After the m-RNA-based vaccine developed by the US pharmaceutical company Pfizer and the German biotechnology company BioNTech against Kovid-19, a new vaccine was announced.. Pfizer and BioNTech signed a collaboration agreement to develop the first m-RNA-based vaccine against shingles.
One of the founders of BioNTech, Prof.. Dr.. Uğur Şahin, said, “The agreement in question aims to develop a new m-RNA-based vaccine against shingles by using the expertise and resources of both companies.”.
CLICK TO MAKE A VACCINE APPOINTMENT…
Ugur Şahin Announced! A New Vaccine Is Coming!
In the written statement on BioNTech’s website, it has started research, development and trade for the vaccine planned to be produced against shingles, one of the infectious diseases transmitted by viruses. It has been announced that an agreement has been made regarding. Here are the details about shingles, which is a recurrent disease, and the new shingles vaccine… >
In order to develop the shingles vaccine with m-RNA technology, it was noted that scientists from both companies will start working on the platforms used in the development of the Kovid-19 vaccine.
According to the agreement. Pfizer will reportedly pay BioNTech US$225 million upfront, BioNTech will reportedly pay Pfizer $25 million for its proprietary antigen technology. It was emphasized that Pfizer-BioNTech’s first clinical trials of the shingles vaccine are planned to start in the second half of 2022.
UĞUR ŞAHİN: A NEW M-RNA-BASED VACCINE AGAINST shingles
<
In a written statement, one of the founders of BioNTech Prof.. Dr.. Uğur Şahin said,The agreement in question aims to develop a new m-RNA-based vaccine against shingles using the expertise and resources of both companies..